Oral GLP-1s Fuel Health-Tech Boom as Safety Research Lags

Oral GLP-1s Fuel Health-Tech Boom as Safety Research Lags Eli Lilly (LLY) and Novo Nordisk (NVO) now command a combined market capitalization north of $1.5 trillion, a valuation built on the blockbuster success of their injectable GLP-1 drugs for diabetes and weight loss. As both companies pivot toward oral formulations, promising to broaden the addressable market exponentially, a secondary boom in health technology is accelerating. This rally, however, is running ahead of comprehensive research into the drugs' long-term safety, a gap that is drawing scrutiny from analysts. ## Background The market tape has been dominated by the GLP-1 trade. Shares of Eli Lilly have climbed over 80% year-to-date, while Novo Nordisk is up more than 40%, distorting the performance of the entire healthcare sector and S&P 500. This performance is based on massive sales of injectable drugs like Wegovy (NVO) and Zepbound (LLY). The next leg of growth is predicated on oral versions, which would remove the barrier of injections for millions of potential users. This has sent valuation multiples—ratios comparing stock price to a metric like earnings per share (EPS)—to levels that price in significant future growth. For context, LLY trades at a forward price-to-earnings multiple of over 60, compared to roughly 21 for the S&P 500. Investor positioning has been firmly long the two pharma giants, creating narrow market breadth, where a small number of stocks drive index gains. The enthusiasm has spilled over into a new ecosystem of venture-backed startups offering digital coaching, side-effect management apps, and specialized meal delivery for GLP-1 users. These companies' business models are entirely dependent on sustained, widespread adoption of the drugs. Corporate guidance, or a company's own forecast, from both NVO and LLY has consistently been revised upward, fueling the rally. But this momentum assumes a smooth regulatory and safety pathway that is not guaranteed. ## Why it matters The key read-through extends beyond big pharma to the nascent health-tech sector and the venture capital that funds it. The market is pricing in a seamless expansion from injectables to pills, and from specialized use to mass adoption. Any disruption to that narrative poses a significant risk. Known side effects are primarily gastrointestinal, but questions remain about long-term cardiovascular effects and rarer issues that may only appear in larger populations over longer timeframes. The research and post-market surveillance to answer these questions are lagging the market's valuation of the opportunity. On the wrong side of this trade are investors who have underwritten the growth of the GLP-1 support ecosystem without pricing in regulatory or safety risk. A new, serious adverse event finding could trigger swift action from the Food and Drug Administration (FDA), potentially leading to revised warning labels, usage restrictions, or a delay in approving new oral versions. Such a development would not only hit the valuations of NVO and LLY but could render entire business models in the adjacent health-tech space unviable overnight, stranding capital. ## What to watch Investors are watching for any new clinical trial data on the long-term safety and efficacy of oral GLP-1s. An FDA decision on a new oral drug or an expansion of indications for existing ones will be a critical catalyst. The next earnings calls from Novo Nordisk and Eli Lilly will be scrutinized for any change in guidance or commentary related to the oral rollout and adoption trends. By September 30, 2024, the market expects more clarity. If safety concerns are sufficiently addressed by new research and the regulatory pathway remains clear, sales forecasts and investment in the supporting tech ecosystem will likely accelerate. Should significant new safety risks emerge, however, expect a sharp, downward re-rating of growth potential for the entire GLP-1 complex.